News

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...
Nature5d
How to keep weight off after obesity drugs
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...
Injectable medications for obesity found to produce smaller weight loss in a real-world setting
A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...
EurekAlert!6d
Cleveland Clinic research finds injectable medications for obesity produce smaller weight loss in a real-world setting, compared to randomized clinical trials
UNDER EMBARGO UNTIL Tuesday, June 10, 2025, 3 a.m. EDT, CLEVELAND: A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...
Weight-loss drugs less effective in 'real-world', study finds
UNDATED (WKRC) - Weight-loss medications may not be as effective in "real-world" settings as they are in clinical trials, ...
Lilly’s Obesity Drug Sales Rise 60% in India Amid Rising Demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...
Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.